Device Trial Radar · NCT01824394
nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation
Last checked: Nov 19, 2026Latest source record: Feb 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
481
Actual
Start
Apr 1, 2013
Primary completion
Nov 26, 2017
Study completion Nov 26, 2017
Sponsor
- Lead sponsor
- Biosense Webster, Inc.Public (JNJ)
- Sponsor type
- Industry
- First posted
- Apr 4, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To demonstrate safety and effectiveness of nMARQ Catheter System \[nMARQ\] compared with THERMOCOOL® Navigational Family of catheters in treating subjects with drug-refractory symptomatic paroxysmal atrial fibrillation (PAF).
Conditions
- Atrial Fibrillation
Interventions
nMARQ Navigation CathetersDevice
NaviStar ThermoCool CathetersDevice
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Early Onset Primary Adverse EventsTime frame: 30 days post-procedure
- Incidence of Early Onset Primary Adverse Events for the Intent-to-Treat and As-Treated PopulationTime frame: 30 days post-procedure
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.